Arca
Skip to content
Tools
Tools

B-cell lymphoma

Drug research and approvals for B-cell lymphoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 784 studies of B-cell lymphoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 74 drug trials for it since 2013, FDA has 26 approved and 23 open orphan designations naming it, and the EU has 7 authorised medicines for it.

  • Recruiting worldwide: 784
  • Trials authorized in Canada: 74
  • FDA orphan approvals: 26
  • EU medicines: 7

Recruiting now

Newest posted first, of 784 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition or a subtype of it, from ChEMBL's drug indications

Approved 10

  • Polatuzumab vedotinDiffuse large B-cell lymphoma · B-cell antigen receptor complex-associated protein beta chain binding agent
  • TafasitamabDiffuse large B-cell lymphoma · B-lymphocyte antigen CD19 binding agent
  • GlofitamabDiffuse large B-cell lymphoma · B-lymphocyte antigen CD20 binding agent
  • Axicabtagene ciloleucelDiffuse large B-cell lymphoma · B-lymphocyte antigen CD19 binding agent
  • Loncastuximab tesirineDiffuse large B-cell lymphoma · B-lymphocyte antigen CD19 binding agent
  • TisagenlecleucelDiffuse large B-cell lymphoma · B-lymphocyte antigen CD19 binding agent
  • SelinexorDiffuse large B-cell lymphoma · Exportin-1 inhibitor
  • EpcoritamabDiffuse large B-cell lymphoma · B-lymphocyte antigen CD20 binding agent
  • VinblastineDiffuse large B-cell lymphoma · Tubulin inhibitor
  • UmbralisibMarginal zone B-cell lymphoma · PI3-kinase p110-delta subunit inhibitor

Phase 3 12 of 60

  • RituximabDiffuse large B-cell lymphoma · B-lymphocyte antigen CD20 binding agent
  • CyclophosphamideDiffuse large B-cell lymphoma · DNA inhibitor
  • PrednisoneDiffuse large B-cell lymphoma · Glucocorticoid receptor agonist
  • DoxorubicinDiffuse large B-cell lymphoma · DNA topoisomerase II alpha inhibitor
  • VincristineDiffuse large B-cell lymphoma · Tubulin inhibitor
  • LenalidomideDiffuse large B-cell lymphoma · CRL4(CRBN) E3 ubiquitin ligase inhibitor
  • GemcitabineDiffuse large B-cell lymphoma · Ribonucleoside-diphosphate reductase RR1 inhibitor
  • CytarabineDiffuse large B-cell lymphoma · DNA inhibitor
  • OxaliplatinDiffuse large B-cell lymphoma · DNA inhibitor
  • ObinutuzumabDiffuse large B-cell lymphoma · B-lymphocyte antigen CD20 binding agent
  • ZanubrutinibDiffuse large B-cell lymphoma · Tyrosine-protein kinase BTK inhibitor
  • IfosfamideDiffuse large B-cell lymphoma · DNA inhibitor

Phase 2 12 of 89

  • VenetoclaxDiffuse large B-cell lymphoma · Apoptosis regulator Bcl-2 inhibitor
  • PembrolizumabDiffuse large B-cell lymphoma · Programmed cell death protein 1 inhibitor
  • NivolumabDiffuse large B-cell lymphoma · Programmed cell death protein 1 inhibitor
  • AtezolizumabDiffuse large B-cell lymphoma · Programmed cell death 1 ligand 1 inhibitor
  • DurvalumabDiffuse large B-cell lymphoma · Programmed cell death 1 ligand 1 inhibitor
  • BlinatumomabDiffuse large B-cell lymphoma · T cell surface glycoprotein CD3 cross-linking agent
  • BusulfanDiffuse large B-cell lymphoma · DNA inhibitor
  • MetforminDiffuse large B-cell lymphoma · Mitochondrial complex I (NADH dehydrogenase) inhibitor
  • PanobinostatDiffuse large B-cell lymphoma · Histone deacetylase inhibitor
  • TacrolimusDiffuse large B-cell lymphoma · FK506-binding protein 1A inhibitor
  • BelinostatDiffuse large B-cell lymphoma · Histone deacetylase inhibitor
  • CopanlisibDiffuse large B-cell lymphoma · PI3-kinase p110-alpha subunit inhibitor

Phase 1 or earlier 12 of 61

  • CarfilzomibDiffuse large B-cell lymphoma · 26S proteasome inhibitor
  • AvadomideDiffuse large B-cell lymphoma
  • IMM-0306
  • Valproic acidDiffuse large B-cell lymphoma · Succinate semialdehyde dehydrogenase inhibitor
  • ZandelisibDiffuse large B-cell lymphoma · PI3-kinase p110-delta subunit inhibitor
  • OnatasertibDiffuse large B-cell lymphoma · Serine/threonine-protein kinase mTOR inhibitor
  • AlisertibBurkitt lymphoma · Serine/threonine-protein kinase Aurora-A inhibitor
  • TanespimycinBurkitt lymphoma · Heat shock protein HSP90 inhibitor
  • VistusertibDiffuse large B-cell lymphoma · Serine/threonine-protein kinase mTOR inhibitor
  • TazemetostatDiffuse large B-cell lymphoma · Histone-lysine N-methyltransferase EZH2 inhibitor
  • ParsaclisibDiffuse large B-cell lymphoma · PI3-kinase p110-delta subunit inhibitor
  • IrinotecanBurkitt lymphoma · DNA topoisomerase I inhibitor

How its trials ended

1,592 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 414 whose ending is known, 38% met their primary endpoint, 3% missed it and 59% stopped early.

  • Ongoing60638%
  • Completed, result not reported36923%
  • Status unknown20313%
  • Met its primary endpoint15610%
  • Stopped: other or unclear956%
  • Stopped: sponsor or business decision574%
  • Stopped: enrollment or feasibility483%
  • Stopped: lack of efficacy242%
  • Stopped: funding161%
  • Missed its primary endpoint141%
  • Stopped: safety4<1%

Trials authorized in Canada

The 10 newest of 74; search them all in Canada trials
Oct 30, 2026A phase 2/3 multi-arm, open-label study of MK-1045 in combination with zilovertamab vedotin in participants with relapsed/refractory diffuse large B-cell…MK-1045 / Zilovertamab vedotin (MK-2140)Merck & Co. (MSD)Pending
Oct 16, 2026A phase 3, open label, randomized study comparing the efficacy and safety of odronextamab (REGN1979), an ANTI-CD20 × ANTI-CD3 bispecific antibody, in…Odronextamab (REGN1979)RegeneronPending
Jul 23, 2026A phase III study to evaluate the efficacy of surovatamig combined with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (r-chop) in…SurovatamigAstraZeneca PharmaceuticalsPending
Apr 10, 2026A phase 3, randomized, open-label, multicenter study evaluating the efficacy of KITE-753 versus axicabtagene ciloleucel in participants with relapsed and/or…KITE-753Kitepharma IncOngoing
Mar 11, 2026A phase 1/2 open-label, multicenter study evaluating the safety and efficacy of KITE-363 or KITE-753, autologous ANTI-CD19/CD20 car T-cell therapies, in…KITE-753Kitepharma IncOngoing
Feb 20, 2026A phase 3 randomized controlled trial of rondecabtagene autoleucel, an autologous, dual-targeting CD19/CD20 car T-cell product candidate, versus investigator’s…Rondecabtagene autoleucelLyell ImmunopharmaOngoing
Jun 20, 2025An open-label, multicenter, phase 1 trial to evaluate the safety, pharmakonetics, and anti-tumour activity of TLN-121 as a single agent and in combination with…TLN-121 / Cyclophosphamide / Lunsumio (mosunetuzumab) / Columvi (glofitamab) /…Treeline BiosciencesOngoing
Mar 7, 2025A randomized, open-label study evaluating the efficacy and safety of cemacabtagene ansegedleucel in participants with minimal residual disease after response…Cemacabtagene ansegedleucelAllogene TherapeuticsOngoing
Dec 13, 2024A randomized, open-label, multicenter, phase 3 study of zilovertamab vedotin (MK-2140) in combination with r-chp versus r-chop in participants with previously…Zilovertamab vedotin (MK-2140) / Rituximab / Cyclophosphamide / Doxorubicin /…Merck & Co. (MSD)Ongoing
Dec 13, 2024A phase II, open-label, multicenter study to evaluate the optimization of the cytokine release syndrome profile for glofitamab in combination with gemcitabine…Columvi / GazyvaRocheOngoing

FDA orphan designations

Approved first, then open designations, newest first; 15 of 49
Feb 5, 2026YescartaTreatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12…Kite Pharma, Inc.Approved
Apr 19, 2023PolivyIn combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients who have…Genentech, Inc.Approved
Jun 24, 2022BreyanziTreatment of adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified…Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyApproved
Jun 24, 2022BreyanziTreatment of adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified…Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyApproved
Jun 24, 2022BreyanziTreatment of adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified…Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyApproved
Apr 1, 2022YescartaTreatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12…Kite Pharma, Inc.Approved
Apr 1, 2022YescartaTreatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12…Kite Pharma, Inc.Approved
Apr 1, 2022YescartaTreatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12…Kite Pharma, Inc.Approved
Dec 2, 2021RituxanTreatment of pediatric patients aged 6 months and older with previously untreated, advanced stage, CD20-positive diffuse large B-cell…Genentech, Inc.Approved
Apr 23, 2021ZynlontaTreatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including…ADC Therapeutics SAApproved
Feb 5, 2021BreyanziTreatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including…Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyApproved
Feb 5, 2021BreyanziTreatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including…Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyApproved
Feb 5, 2021BreyanziTreatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including…Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyApproved
Jul 31, 2020MonjuviMONJUVI® is indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell…Incyte CorporationApproved
Jun 22, 2020XpovioXPOVIO is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise…Karyopharm Therapeutics, Inc.Approved

Medicines authorised in the EU

Newest first
Sep 22, 2023TepkinlyEpcoritamabAbbVie Deutschland GmbH & Co. KGEMA ↗
Jul 7, 2023ColumviGlofitamabRoche Registration GmbHEMA ↗
Dec 20, 2022ZynlontaLoncastuximab tesirineSwedish Orphan Biovitrum ABEMA ↗
Apr 4, 2022BreyanziLisocabtagene maraleucelBristol-Myers Squibb Pharma EEIGEMA ↗
Aug 26, 2021MinjuviTafasitamab · orphanIncyte Biosciences Distribution B.V.EMA ↗
Jan 16, 2020PolivyPolatuzumab vedotin · orphanRoche Registration GmbHEMA ↗
Aug 23, 2018YescartaAxicabtagene ciloleucel · orphanKite Pharma EU B.V.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.